Entropy Neurodynamics Granted South African Patent for Fibromyalgia Treatment Using Psilocybin
MT Newswires Live
Jul 20
Entropy Neurodynamics (ASX:ENP) said it was granted a patent in South Africa covering methods of treating fibromyalgia using psilocybin, with a term extended to September 2043, according to a Monday Australian bourse filing.
The patent provides broad intellectual property protection covering the clinical use of psilocybin for the treatment of fibromyalgia, including therapeutic methods, dosing regimens, patient selection criteria, clinical assessment protocols, biomarkers, treatment outcome measures, integration therapy, and manufacture.
The patent term is subject to the payment of annual renewal fees.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.